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Abstract 
Recruitment processes for clinical trials are governed by guidelines and regulatory systems intended 
to ensure participation is informed and voluntary. Although the guidelines and systems provide 
some protection to potential participants, current recruitment processes often result in limited 
understanding and experiences of inadequate decision support. Many trials also have high drop-out 
rates among participants, which are ethically troubling because they can be indicative of poor 
experiences and they limit the usefulness of the knowledge the trials were designed to generate.  
Drawing on recent social-psychological and philosophical-ethical research on trial recruitment and 
patient participation in treatment decision-making, this paper identifies possibilities for improving 
communicative support for both initial decisions and ongoing participation in clinical trials. It 
highlights the potential of a shift in thinking about ‘voluntariness’, underpinned by relational 
understandings of autonomy, to encourage more nuanced judgements about the ethics of 
communication between trial staff and (potential) participants. The paper suggests that the idea of 
responsively enabling people to consider invitations or requests to participate in particular trials 
could serve as a general guide to communication. This might help ensure decisions about trial 
participation are meaningfully informed and voluntary, and that relationships between trial staff and 
participants contribute to positive experiences of trial participation and ultimately to the generation 
of the robust knowledge. 
(212 words) 
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Introduction 
The norms of research ethics require participation in clinical trials to be ‘informed’ and ‘voluntary’.  
Strong guidance and regulatory systems for monitoring information provision and consent have 
been introduced to ensure that standards of informed and voluntary participation are not sacrificed 
in the pursuit of participant numbers.1,2  These undoubtedly offer people some protection against 
being misled or coerced into trials, but they – and associated approaches to trial recruitment - have 
practical and ethical limitations.3,4 
This paper draws on recent social-psychological and philosophical-ethical research on trial 
recruitment and patient involvement in decision making to critique current approaches to ensuring 
trial participation is informed and voluntary.  It identifies possibilities for improving communicative 
support both for initial decisions for or against participation and for ongoing participation in clinical 
trials. These possibilities warrant careful consideration because they have potential to promote 
more meaningfully informed and voluntary consent, and, by enhancing experiences of participation, 
to reduce participant drop-out and ensure that the resources and effort invested in trials generate 
robust findings. 
 
Informed consent: current guidance and regulations 
Current regulatory guidelines for clinical trials stem from the Declaration of Helsinki.1  As a set of 
ethical principles, the Declaration is not legally binding but is endorsed for example by the 
International Conference on Harmonisation (ICH) guideline for Good Clinical Practice (GCP) and the 
EU Clinical Trials Directive.5  
Current guidelines, regulations and practices intended to ensure that consent is ‘informed’ tend to 
put more emphasis on the information provided to potential trial participants than on the 
understanding these people achieve. They implicitly assume that giving ‘competent’ people 
standardised information will suffice. Guidelines suggest information should be provided about 
(among other things): the fact that the trial involves research; the nature and purpose of the 
intervention(s) being tested; alternatives; risks and benefits; and the requirement that participation 
is voluntary.  Regulatory regimes usually require that the information be presented in writing and 
assessed by research ethics committees before use. People who agree to take part must sign 
consent forms to confirm they have understood the information provided and are participating 
voluntarily. 
Concerns about current approaches 
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Several concerns have been raised about current guidelines, regulations and associated practices. 
These relate to: evidence of limited understanding and experiences of inadequate decision support 
among people invited to participate in trials; the way voluntariness is understood; and the neglect of 
issues affecting participants’ experiences beyond trial entry.  We consider these issues primarily in 
the context of Phase III randomised controlled trials which test interventions that have passed initial 
safety tests to identify how well they work. Most points also apply to other clinical trials.  
  
Limited understanding and experiences of inadequate decision support  
It is increasingly recognised that standardised information provision does not lead to uniform 
understanding (or even uniformly adequate understandings),6 and that the self-reports of 
understanding that people provide in conversations with trial staff and on consent forms may be 
misleading.7 Several studies, including qualitative investigations in which people have discussed their 
experiences of trials they have been invited to join, have shown that, even after receiving 
information that complies with regulatory guidance, consenting participants sometimes 
misunderstand key features of trials in which they are enrolled.6   
 
Knowledge of the key features of a trial and recognition that participation is optional may not suffice 
to ensure people make ‘good’ (informed and personally appropriate) decisions about their 
participation. Their understanding needs to include an appreciation of the potential implications of 
trial participation in their own situation and for what matters to them personally. 
 
Although measures have been developed to assess people’s understanding or ‘decisional capacity’ in 
clinical research contexts, these operationalise understanding in limited ways.  Some check people’s 
ability to repeat or recall information without considering their comprehension, and some focus on 
knowledge of the trial in a general sense without considering their appreciation of the trial’s 
implications for them personally.  Their validity is sometimes unclear.8 
 
Shortfalls in (potential) participants’ understanding can often be linked to problems with both formal 
trial information resources (participant information sheets etc) and/or conversations involving trial 
staff.  
Formal trial information resources are often quite lengthy. This may be more appropriate for some 
trial situations and potential participants than others. People who satisfy basic competence criteria 
have: diverse but often limited literacy skills; varied understandings of their health issues, potential 
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interventions and clinical trials; and different experiences, attitudes and capabilities relating to 
decision-making about their healthcare and participation in social activities. Those who are less able 
to process, appraise and use written information for themselves are more prone to make poor 
decisions about whether or not to take part. 
 
Current guidance acknowledges that individuals may have ‘specific information needs’ and require 
customized methods of information delivery, but it says little about what forms of customization are 
acceptable.2  In practice, trial teams usually default to providing more rather than less information to 
pass regulatory requirements.9  Too much information, however, can overburden people, discourage 
engagement and/or impair decision making.3,9  Attempts to re-order or condense information 
presented in formal trial resources may be helpful, but limitations in the assessment of 
understanding render their overall effects unclear.6 
 
The relative inflexibility of formal information resources might be compensated by opportunities for 
more flexible communication in conversations between potential participants and trial staff 
(including clinicians involved in recruitment). However, the less readily regulated information 
provision that occurs in these conversations may itself be problematic. Trial staff might, for example, 
be more pressured and concerned to recruit participants than to ensure potential participants have 
a good understanding of key issues. Some staff lack the knowledge and communication skills to 
facilitate the development of understanding, and various biases may arise in trial staff’s presentation 
of options.  An analysis of early consultations about a trial comparing treatments for prostate cancer 
found that trial staff spent more time discussing some treatments than others, leading potential 
participants to develop preferences.10  Corrective action resulted in improved presentations in the 
later stages of this trial,10 but in many trials the quality of conversational information provision is 
unknown. Intensive training to improve communication during trial recruitment consultations can 
improve staff skills in a number of domains,11 but such intensive training is not universally given.  
 
Overall, questions about the adequacy of information provision and broader forms of supportive 
communication for the deeper, personalised understanding and decisional confidence needed for 
‘good’ decision-making seem somewhat neglected in current guidance and practice. This may in part 
reflect prevailing ways of thinking about ‘voluntariness’, which tend to limit the forms of support 
that are recognised as appropriate.12  We consider this issue next. 
 
Thinking about voluntariness 
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The requirement for voluntariness is intended to ensure that potential trial participants are not 
subject to coercion or other unethical influences. This is an appropriate goal, but some ways of 
thinking about voluntariness reflect an outdated view of the ethical principle of respect for patient 
autonomy and might impair practical attempts to promote it.13 
 
In healthcare contexts, the principle of respect for autonomy is usually understood in terms of 
respect for autonomous choices, which are defined as choices made intentionally and with sufficient 
understanding and voluntariness, or freedom from controlling influences.14  This definition is often 
understood and used in quite limited ways that at least implicitly rely on the unrealistic assumption 
that people are rational and isolated individual decision-makers.12,13,15,16  These understandings and 
uses seem to neglect key issues in terms of how people consider and consult with others in decision-
making.16 They support a tendency to equate ‘voluntary’ choice with ‘independent’ choice, and to 
think that health professionals should not help in ways that might ‘direct’ or ‘interfere’ with 
individual patients’ preferences.12,13,17  
 
Thinking in this vein can discourage the provision of some potentially supportive forms of 
communication. For example, while prevailing ideas about respect for autonomous choices can 
readily be used to justify clinicians challenging the beliefs a patient exhibits if those beliefs are 
demonstrably false,14 it is less clear whether and how they can justify helping a person who 
understands the key facts but is unsure of their preferences or lacks confidence to choose.18  It is 
likely that clinicians’ concerns not to interfere lie behind the many anecdotes of patients feeling 
‘abandoned’ when forced to make their own treatment choices. There is some evidence of similar 
troubling experiences among people who are given information then left alone to decide about trial 
participation.19  
 
Experiences of participation beyond trial entry 
Current guidance and most work on communication and experiences of trial participation pays little 
attention to what happens after people enter trials – at least until trial results are available. 
However, trials often have problems with participants refusing to accept their treatment allocation 
after randomisation, not completing data collection, and otherwise ‘dropping out’.20 Some of these 
problems might be rooted in inadequate support for decision-making about trial entry.  There is 
some evidence that participants who withdraw from trial have difficulties with the trial 
information.20 And people who enter a trial with a strong preference for one intervention may suffer 
from resentful demoralisation and not persist if they are allocated to another intervention.   
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There are also various reasons why participants’ situations, beliefs and expectations may change 
during the course of the trial.  Such changes generate needs for clarification and supportive 
communication that are not always met.21 
 
The drop out of trial participants due to preventable poor experiences and inadequate 
communicative support from trial staff is ethically troubling for several reasons.  Apart from direct 
concerns about how human volunteers are treated, reduced participant numbers can seriously 
affect the robustness of the knowledge that the trial was designed to generate. 
 
Thinking ahead: ideas for improvement 
The concerns outlined above have prompted several innovative developments by trialists. Insights 
from recent work on patient involvement in treatment decision-making also suggest possibilities for 
improvement in trial contexts. We review their potential in this section.  
 
Patient led consultations 
A recent study of trial recruitment conversations led to a distinction being made between 
consultations involving ‘recruiter-led’ rehearsals of standard lists of topics prioritised by informed 
consent guidance, and more flexible consultations driven by questions  potential participants 
wanted to discuss after reading participant information sheets.22  ‘Patient led’ consultations were 
associated with higher rates of acceptance of treatment allocation after randomisation.22 However, 
this promising strategy might not suit all potential participants: some are likely to struggle to identify 
and get their agendas addressed in consultations even if recruiters seek to facilitate this.  
  
Decision-support 
A range of decision support interventions (DeSIs), or decision aids, have been developed in recent 
decades to help people facing diverse choices about healthcare options. DeSIs have been evaluated 
in several treatment and screening contexts and found to have positive effects on knowledge and 
several other outcomes associated with decision quality. 23 Interest is now turning to  the question of 
whether potential trial participants might benefit from the use of DeSIs within or alongside formal 
trial information resources.  Several authors have hypothesised that DeSIs might: help people to see 
the structure of the choice(s); facilitate direct comparisons of options (including options to 
participate or not) by presenting equivalent information about each; and encourage people to think 
about what matters most to them.24,25There have, however, been few empirical tests of their 
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hypotheses to date. In one study, a decision aid was tested among women who had already agreed 
to take part in a trial comparing two drugs for Ductal Carcinoma In Situ: these women found it 
helpful and thought it increased their understanding beyond what they had learned from the trial’s 
approved participation sheet.26 In another study, an explicit values clarification task of the kind 
associated with decision aids was tested among healthy women who were asked to consider a 
hypothetical decision about trial participation. Those who were given the explicit values clarification 
task evaluated more information in the light of their personal values and expressed lower 
ambivalence and decisional uncertainty than those who were not.27  
 
Given current regulatory requirements, formal evaluations of DeSIs may be difficult to mount in ‘live’ 
trial contexts, particularly if they seek to compare DeSIs with current standard approaches.24   And 
the design of both DeSIs and evaluation studies will require careful thought and research. If used as 
stand-alone resources, DeSIs may be too complex for some people unless they are highly 
sophisticated and interactive, but the development of sophisticated and interactive DeSIs may be 
too costly to seem warranted in small to medium scale trials. DeSIs may not suffice to avoid or to 
check for the problems that can arise with people’s understandings and preferences relating to trials 
and the interventions they evaluate. They are also unlikely to substitute for the valued forms of 
support that people can derive from good interpersonal relationships with healthcare or trial staff, 
especially in high stakes situations.28 
 
Conversational explorations by trial staff of potential participants’ treatment preferences might also 
be helpful. In a recent study, these were shown to promote more informed decisions about 
participation in a prostate cancer treatment trial.29 As noted above, however, some ways of thinking 
about voluntariness tend to discourage this kind of intervention.  
 
 
Rethinking voluntariness: justifying broader forms of support 
Broader forms of supportive communication can in principle be justified as respectful of person 
autonomy using relational understandings of autonomy which de-emphasise ideas of isolated 
‘independence’ in choice.15,17 Relational understandings have emerged as philosophers have 
grappled with the question of what personal autonomy can mean if we take seriously the profound 
ways in which our social and cultural environments and networks of relationships influence how 
people can and want to shape their individual lives.30,31  Relational understandings recognise that our 
capabilities for autonomy (including skills for self-discovery, self-definition and self-direction) are 
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socially influenced and can be situationally modified.30,31   They draw critical attention to the different 
ways in which our social relationships and interactions – including with family members and 
clinicians - can support or undermine the development and exercise of autonomy capability,15,32 and 
they discourage a simple equation of voluntariness with either selfish or independent or isolated 
action.16,17  
 
Relational understandings highlight the potential value of some professional intervention as 
supportive of the development and exercise of autonomy by individual patients.13,15,32  They do not 
sanction an ‘anything goes’ approach to communication about trial participation, but can encourage  
nuanced and context sensitive explorations of the appropriateness of various forms of 
communication. However, as work on their application in the context of treatment decision-making 
has highlighted, they are likely to require high communication skill levels and flexible virtuous 
practice by trial staff to ensure their engagement with each individual is in effect autonomy 
supportive.12 This raises questions about whether and how staff should be encouraged to use 
broader forms of support in practice, and how their practice (as well, perhaps, as the influence of 
family members) should be monitored.12,17 
 
Although it is difficult to monitor the adequacy or appropriateness of trial-related communications 
in context sensitive ways that give credit to appropriate flexibility, modifications to consent forms 
might help to some extent.  Participants are currently asked to affirm on consent forms that their 
participation is voluntary. Although their understandings of voluntariness are likely to vary, their 
responses are generally assumed to be valid.  With a little methodological development, questions 
to both participants and non-participants might serve to monitor how people are invited to join 
trials.  Checks could be made not just on knowledge/understanding but also on experiences of staff 
support, decisional certainty/uncertainty, decisional confidence/regret, congruence of attitudes and 
action, and decisional ownership.  Potential participants’ qualitative comments about the ways trial 
staff and others communicated with and influenced them could also generate useful insight. 
 
A guiding ethos or approach 
Ideas about various text based and conversational information and decision support interventions 
could perhaps be usefully be integrated within a broader (and more broadly applicable) ethos or 
approach to communication that could serve to guide the provision of robust but flexible support to 
people who are invited to take part in trials.  One option that has been introduced for 
communication about screening is the ‘consider an offer’ approach.33  Although screening programs 
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have different objectives than clinical trials, some similar issues arise, and a modified version of the 
approach might be a useful starting point for thinking about communication in clinical trial settings. 
 
The ’consider an offer’ approach for communicating about screening was developed because two 
prevailing approaches - labelled ‘be screened’ and ‘analyse and choose’ – both had significant 
limitations.33 The ‘be screened’ approach aims to persuade people to have screening. It is 
characterised by: encouragement to be screened; information provision that emphasises the 
potential benefits of screening and de-emphasises the potential harms; and a lack of recognition 
that some people might reasonably prefer not to be screened. This approach fails to reflect the 
benefit-harm profile of screening tests and limits scope for informed choice.33 Current regulations 
relating to clinical trials clearly preclude a parallel ‘participate’ approach for similar ethical reasons. 
The contrasting ‘analyse and choose’ approach aims to ensure that individuals make informed 
choices about screening. It is characterised by the provision of comparative data about the various 
outcomes of being screened or not. This approach can be criticised for potentially: imposing an 
unnecessary burden of detailed decision analysis;  leading to poor decision making (because too 
much information and pressure to make the best choice can be unhelpful); and deterring uptake of 
effective and appropriate screening.33  These concerns clearly parallel those mentioned above in 
relation to increasing information provision for potential trial participants, thus leaving them alone 
to work out whether or not to participate. 
 
The ‘consider an offer’ approach aims to avoid the pitfalls of ‘be screened’ and ‘analyse and choose’ 
approaches to communicating about screening. It seeks to support personal autonomy without 
overburdening people with unwanted information and decision-making tasks, and without deterring 
uptake of effective and personally appropriate screening.33 The approach involves explaining an 
offer or recommendation of screening and enabling people to consider that by: providing responsive 
information and discussion support to facilitate personal assessments of the offer; being clear that 
even recommended offers might reasonably be declined; and ensuring people feel safe getting the 
support they need to make a decision that is right for them.12  Some basic features suggested by the 
‘consider an offer’ approach are given in the box. A similar ethos or guiding approach for 
communicating about clinical trials might be labelled, ‘consider an invitation/request’.   
 
Adoption of the ‘consider an invitation/request’ ethos or approach would not necessitate any 
particular communication interventions. It might, for example, be delivered with or without the use 
of DeSIs or patient led-consultations. It might encourage provision of shorter information resources 
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and more emphasis on opportunities for responsive communicative support to help people consider 
their potential participation, but would not dictate that one particular format or combination was 
right for all trial contexts. The approach is characterised primarily by its grounding in relational 
understandings of people and their responsibilities and capabilities (especially for autonomy) and by 
its orientation to ensure that information provision and communication with potential participants 
(a) enable development of the kinds of understanding required for personally appropriate decision-
making and (b) reflect a commitment to promote the kinds of voluntariness in decision-making that 
can emerge from within personally supportive relationships.  
 
The ‘consider an invitation/request’ approach requires flexibility to ensure appropriate 
responsiveness to diverse individuals and situations. This will make it difficult to monitor and 
evaluate, especially according to the methods usually privileged in considerations of evidence of 
effectiveness. However, its potential to encourage attention to the overall tone and implication of 
communication, and to enable diverse people to engage more effectively and confidently in 
decisions about trial participation warrants  careful investigation in practice. 
 
Looking beyond trial entry 
The supportive intent of a ‘consider an invitation/request’ approach could readily be continued 
beyond the point of trial entry.  The ethos, or guiding approach, could be extended into the 
development and use of communication opportunities at key points in trial participation, for 
example after delivery of a major intervention or at meaningful chronological intervals during follow 
up.  These communication opportunities could serve multiple overlapping purposes, for example to: 
remind participants of the aim and key features of the trial; encourage and support contribution to 
all data collection points; express appreciation for participants’ ongoing contributions; and listen to 
participants’ experiences to inform future trial communications. Recurring communication points 
could allow trial staff to recognise and relate to participants as individuals, and several studies 
suggest this is valuable. For example, the importance of good organisation and ongoing 
communication was highlighted in  a trial of nutritional interventions for older people,34 and 
empathic engagement during the delivery of an intervention contributed to people feeling valued 
and continuing as participantsin a trial of acupuncture.35 
 
Conclusion 
There is significant scope to improve on current communication relating to trial participation. Recent 
social-psychological and philosophical-ethical research suggests a number of possibilities for 
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development.  These include extending communicative support beyond standardised information 
provision and beyond initial decisions about participation, and adopting an overall ethos or approach 
to communication that is oriented to enable people to understand and respond in personally 
appropriate ways to invitations/requests to participate in trials.   
 
There are, of course, resource implications associated with these possibilities.   It costs, for example, 
to develop decision aids, to promote trial staff’s familiarity with relational understandings of 
autonomy, to train them in advanced communication techniques, and to build responsive 
relationships with participants over a series of interactions. There are also some ethical risks: in 
unscrupulous hands, encouragement to intervene supportively might undermine patients’ 
autonomy.  However, investments in good communication may generate cost savings elsewhere, 
and there are various ethical and epistemological advantages to be claimed if the efforts result in 
fewer people feeling they are inadequately supported to respond to an invitation to join a trial, 
declining participation because they are poorly informed, participating on the basis of poorly 
grounded preferences, or dropping out because of poor experiences of participation. Given their 
potential to promote meaningfully informed and voluntary participation in clinical trials, broader 
forms of supportive communication warrant further consideration. 
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Box: Key features of ‘Consider an invitation/request’ approach 
Based on the ‘consider and offer’ approach to communication, which was originally developed 
for decisions about screening30 communication about clinical trials within the ‘consider an 
invitation/request’ approach aims to support personal autonomy but without overburdening 
people with unwanted informational details or decisional tasks and without deterring personally 
appropriate trial participation. The approach seeks to help people to consider 
invitations/requests to participate in particular trials, for example by: 
1. providing accessible initial presentations of the invitation/request (e.g. short summary 
sheet, video or brief introductory discussion) and;  
2. ensuring initial presentations are accompanied or followed by opportunities to access 
flexible forms of decision support (including more detailed information and ‘no pressure’ 
discussions) to help people as required to: 
 Assess the rationale behind the trial and the invitation/request to participate 
 Consider the relevance and implications of their own participation or non-participation 
(this may involve thinking through potential benefits and harms to others as well as to 
themselves) 
 Assess the interests and  trustworthiness of trial organisers and staff 
 ‘Sound out’ their initial ideas about whether or not they want to participate and why, 
and perhaps to hear how and why other people have decided for and against 
participation, before they ‘commit’ to a decision 
3. Reassuring people that decisions for and against participation can be reasonable and will be 
respected (not just that decisions against participation will not affect the quality of their 
healthcare).  
Within the overall approach, particular communications should be tailored for specific trials and 
potential participants. 
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